Brief: Expres2ion Announces Bavarian Nordic Enters Agreement
06/05/2020 07:54
May 6 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST :
* EXPRES2ION ANNOUNCES BAVARIAN NORDIC ENTERS AGREEMENT WITH ADAPTVAC TO ADVANCE THE
COVID-19
VACCINE PROGRAM
* EXPRES2ION BIOTECH HOLDING AB - JOINT VENTURE ADAPTVAC HAS ENTERED INTO AN EXCLUSIVE HEAD
OF
TERMS AGREEMENT WITH BAVARIAN NORDIC TO LICENSE COVID-19 VACCINE
Source text for Eikon: ID:nWkrbHfFTL
Further company coverage: EXPRS2.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations